632 related articles for article (PubMed ID: 33256621)
1. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
[TBL] [Abstract][Full Text] [Related]
2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
3. Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol.
Lugani F; Angeletti A; Ravani P; Vivarelli M; Colucci M; Caridi G; Verrina E; Emma F; Ghiggeri GM
BMJ Open; 2021 Nov; 11(11):e052450. PubMed ID: 34845071
[TBL] [Abstract][Full Text] [Related]
4. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Ravani P; Bonanni A; Ghiggeri GM
BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome.
Basu B; Mahapatra TK; Mondal N
Pediatrics; 2015 Jul; 136(1):e132-9. PubMed ID: 26101364
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.
Sinha A; Puraswani M; Kalaivani M; Goyal P; Hari P; Bagga A
Kidney Int; 2019 Jan; 95(1):210-218. PubMed ID: 30497684
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial.
Basu B; Sander A; Roy B; Preussler S; Barua S; Mahapatra TKS; Schaefer F
JAMA Pediatr; 2018 Aug; 172(8):757-764. PubMed ID: 29913001
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
Sinha A; Gupta A; Kalaivani M; Hari P; Dinda AK; Bagga A
Kidney Int; 2017 Jul; 92(1):248-257. PubMed ID: 28318625
[TBL] [Abstract][Full Text] [Related]
9. Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil
Ehren R; Benz MR; Doetsch J; Fichtner A; Gellermann J; Haffner D; Höcker B; Hoyer PF; Kästner B; Kemper MJ; Konrad M; Luntz S; Querfeld U; Sander A; Toenshoff B; Weber LT;
BMJ Open; 2018 Oct; 8(10):e024882. PubMed ID: 30309995
[TBL] [Abstract][Full Text] [Related]
10. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
[TBL] [Abstract][Full Text] [Related]
11. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
[TBL] [Abstract][Full Text] [Related]
12. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
[TBL] [Abstract][Full Text] [Related]
13. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Iijima K; Sako M; Oba M; Tanaka S; Hamada R; Sakai T; Ohwada Y; Ninchoji T; Yamamura T; Machida H; Shima Y; Tanaka R; Kaito H; Araki Y; Morohashi T; Kumagai N; Gotoh Y; Ikezumi Y; Kubota T; Kamei K; Fujita N; Ohtsuka Y; Okamoto T; Yamada T; Tanaka E; Shimizu M; Horinochi T; Konishi A; Omori T; Nakanishi K; Ishikura K; Ito S; Nakamura H; Nozu K;
J Am Soc Nephrol; 2022 Feb; 33(2):401-419. PubMed ID: 34880074
[TBL] [Abstract][Full Text] [Related]
15. Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome.
Kari JA; Alhasan KA; Albanna AS; Safdar OY; Shalaby MA; Böckenhauer D; El-Desoky SM
Pediatr Nephrol; 2020 Aug; 35(8):1445-1453. PubMed ID: 32337638
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
Bagga A; Hari P; Moudgil A; Jordan SC
Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome.
Tellier S; Dallocchio A; Guigonis V; Saint-Marcoux F; Llanas B; Ichay L; Bandin F; Godron A; Morin D; Brochard K; Gandia P; Bouchet S; Marquet P; Decramer S; Harambat J
Clin J Am Soc Nephrol; 2016 Oct; 11(10):1777-1782. PubMed ID: 27445161
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
Fujinaga S; Hirano D; Nishino T; Umeda C; Watanabe Y; Nakagawa M
Pediatr Nephrol; 2019 Nov; 34(11):2417-2421. PubMed ID: 31435725
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study.
Ravani P; Lugani F; Pisani I; Bodria M; Piaggio G; Bartolomeo D; Prunotto M; Ghiggeri GM
Pediatr Nephrol; 2020 Aug; 35(8):1437-1444. PubMed ID: 32232637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
